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Ventricular fibrillation during coronary angiography with
Renografin-76 (meglumine sodium diatrizoate) has been
attributed to the calcium-binding additives sodium ci-
trate and sodium ethylenediaminetetraacetic acid (EDTA),
which may produce repolarization changes manifested
as prolongation of the QT interval. Angiovist-370 is a
newer form of meglumine sodium diatrizoate that con-
tains calcium EDTA as its additive and thus has a de-
creased calcium-binding effect. Eight hundred sixteen
patients were prospectively randomized to receive either
Renografin-76 or Angiovist-370. Ventricular fibrillation
occurred in to of 410 patients receiving Renografin-Ze
and in 0 of 406 patients given Angiovist-370(p < 0.0005).
Clinical data were analyzed without knowledge of
other data in the 10 patients treated with Renografin-76
who had ventricular fibrillation (Group I), 103randomly
selected patients who also received Renografm-76 but
had no ventricular fibrillation (Group II) and 108 ran-
domly selected patients given Angiovist-370 (Group III).
Of several variables examined, only the QT interval dif-
ferentiated patients receiving Renografin-76 and An-
Ventricular fibrillation during coronary angiography occurs
in 0.6 to 1.3% of patients (1-5). It is unclear why some
patients develop this potentially life-threatening complica-
tion of coronary angiography; however, it has been sug-
gested that ventricular fibrillation during coronary angiog-
raphy is a result of the electrophysiologic effects of the
contrast media (6-13). Specifically, it has been observed
that contrast agents cause a prolongation of repolarization
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giovist-370. The mean corrected QT interval (QTc in-
terval) before coronary angiography was slightly but not
significantly (p =0.7) higher in Group I than in Groups
II and III. Ten seconds after the first left coronary artery
injection it was more prolonged in Groups I and II (0.552
and 0.561 second, respectively) than in Group III (0.448
second) (p < 0.00005). Similarly, 10 seconds after the
first right coronary artery injection it was significantly
longer in Groups I and II (0.545 and 0.544 second) than
in Group III (0.477 second) (p < 0.00005). The mean
QTc interval after coronary angiography was slightly
more prolonged in Groups I and II (0.469 and 0.455
second) compared with Group III (0.439 second) (p =
0.06).
Thus, the substitution of calcium EDTA in contrast
agents significantly decreases the incidence of ventricular
fibrillation during coronary angiography, perhaps by
attenuating the repolarization changes (with resultant
QT interval prolongation) induced by contrast agents.
(J Am Coli CardioI1987;10:1249-53)
(with resultant QT interval prolongation) (13). A proposed
factor responsible for these repolarization changes has been
the presence of the calcium-binding additives sodium citrate
and sodium ethylenediaminetetraacetic acid (EDT A) found
in Renografin-76, the most commonly used formulation of
meglumine sodium diatrizoate (14). Preclinical studies have
found a reduced incidence of ventricular fibrillation during
coronary angiography when using either calcium-enriched
Renografin-76 (6) or a newer formulation of meglumine
sodium diatrizoate, Angiovist-370 (15), which contains cal-
cium EDT A as its additive, and thus has a reduced pro-
pensity to bind calcium. The purpose of this investigation
was to prospectively determine whether the incidence of
ventricular fibrillation during coronary angiography in hu-
mans could be reduced with a calcium-enriched contrast
agent, and whether that reduced incidence of ventricular
fibrillation could be correlated with changes in repolariza-
tion as measured by the QT interval.
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Methods
Study patients. Eight hundred sixteen consecutive pa-
tients undergoing cardiac catheterization for the diagnosis
of coronary artery disease or valvular heart disease at the
Hospital of the Medical College of Pennsylvania from March
1984 through the end of March 1985 were randomly as-
signed to receive either Renografin-76 (Squibb and Sons,
Inc.) or Angiovist-370 (Berlex Imaging, Inc.). Approval
was granted by the Committee for the Protection of Human
Subjects, and informed consent was obtained from all pa-
tients. Patients undergoing percutaneous transluminal coro-
nary angioplasty or thrombolytic therapy were excluded from
the study. Coronary arteriography was performed in mul-
tiple right and left anterior oblique projections, using either
the Judkins or Sones technique. Left ventriculography was
performed in the 30° right anterior oblique projection. Pre-
medication consisted of oral administration of 50 mg of
diphenhydramine hydrochloride and either 10 mg of diaze-
pam or 50 mg of pentobarbital.
Data collection. Standard 6 lead electrocardiograms were
recorded using an Electronics for Medicine or Honeywell
Meddars paper recorder at 25 to 100 mmls paper speed.
Electrocardiograms were obtained before the catheteriza-
tion, up to 10 seconds after the first left and right coronary
artery injections and within 5 minutes of completion of the
catheterization.
Clinical characteristics, heart rate and QT intervals were
obtained for all 10 patients who had ventricular fibrillation
during coronary angiography (Group I) . Similar variables
were measured in every fourth patient selected at random
for subgroup analysis. This included 103 patients receiving
Renografin-76 (Group II) and 108 patientsstudied with An-
giovist-370 (Group 1II).
QT intervals from each electrocardiogram were mea-
sured by one of three investigators who did not know which
contrast agent was used. T wave termination was taken as
the transection of the baseline with a line parallel to the
rapidly descending portion of the T wave; U waves were
excluded. The longest QT interval in any standard lead was
used and corrected for heart rate by Bazett's formula:
QTQTc • r.:;-;:: (16).
vRR
Statistical analysis. Ventricular fibrillation incidence rates
were compared using a chi-square analysis. Clinical char-
acteristics, heart rate and QT intervals were analyzed by
two factor analysis of variance , followed by simple main
effects analysis and Tukey-A post hoc tests. Results were
considered significantly different when p < 0.05.
Table 1. Clinical Characteristics of 221 Patients
Group I: Group II: Group Ill :
n = 10 n = 103 n = 108
Characteristics n (%) n (%) n (%)
Age* (yr) 61 ± 4 57 ± I 55 ± 1
Sex
Male 4 (40) 77 (72) 71 (66)
Female 6 (60) 29 (27) 37 (34)
History of previous MI 4 (40) 50 (47) 9 (9)
History of prior VTIYF 0(0) 8 (8) 8 (9)
Medications
Digoxin 1 (10) 8 (8) 7 (7)
Beta-blockers 6 (60) 62 (60) 55 (5 1)
Calcium-blockers 2 (20) 52 (50) 44 (4 1)
Diuretics 3 (30) 27 (26) 23 (2 1)
Type I antiarrh ythmic agents 0 (0) I (I ) 3 (3)
Ejection fraction* 0 .60 ± 0.07 0.64 ± 0.02 0.64 ± 0.01
Cardiac catheterization diagnosis
Coronary artery disease 7 (70) 75 (73) 70 (65)
One vessel 2 (20) 20 (19) 22 (20)
Two vessel 2 (20) 19 (18) 20 (19)
Three vessel 2 (20) 27 (27 ) 20 (19)
Left main I (10) 9 (9) 8 (7)
Valvular heart disease 0 5 (5) 2 (2)
Other (ASD, HCM) 0 0 2 (2)
*Mean ± standard error of the mean. Group I = ventricular fibrillation after Renograph in-76;
Group II = no ventricular fibrillation after Renographin -76; Group III = Angiovist-370. ASD = atrial septal
defect; HCM = hypertrophic cardiomyopathy; MI = myocardial infarction; VTIYF = ventricular tachycardia!
ventricular fibrillation.
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Figure I. Mean QTc interval in patients in Group I (patients re-
ceiving Renografin -76 who had ventricular fi brillation), Group II
(patients receiving Renografin-76 who did not have ventricular
fibrillation) and Group III (patients receiving Angiovist-370) be-
fore, during and after coronary angiography. LCA = left coronary
artery; RCA = rightcoronary artery. *p < .00005 . compared with
Groups I and II; **p = 0.06. compared with Groups I and II.
Results
Incidence of ventricular fibrillation. Of the 4 I0 pa-
tients randomly assigned to receive Renografin-76. 10 pa-
tients (2.4%) had ventricular fibrillation, all of whom sur-
vived this event with no adverse aftereffects. Ventricular
fibrillation occurred in four patients after right coronary
artery injection and in six patients after left coronary artery
injection. There were no episodes of ventricular fibrillation
in the 406 patients who received Angiovist-370 (p < 0.00(5).
Clinical features. Clinical characteristics of the 10 pa-
tients given Renografin-76 who had ventricular fibrill ation
(Group 0, as well as 103 randomly selected patients re-
ceiving Renografin-76 with no ventricular fi brillation (Group
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II) and 108 patients given Angiovist-370 (Group III) are
shown in Table I. There were no significant differences
among the groups with respect to age. sex. history of pre-
vious myocardial infarction, history of prior ventricular
tachycardia or ventricular fibrillation , or current medica-
tions. A very small percentage of patients were taking type
I antiarrhythmic drugs, and none were taking type III anti-
arrhythmic agents. The groups were also similar with regard
to severity of coronary artery disease and left ventricular
function. Serum potassium inGroups I. II and III was 4. 1 ±
0.1, 4.2 ± 0.04 and 4.1 ± 0.04 mEqlliter, respectively.
QT intervals. The mean QTc interval ± SEM within
each group is shown in Figure I. Before coronary angi-
ography the QTc interval was longer in Group I than in
Groups II and Ill. but this difference did not reach statistical
significance (p = 0.7). After initial left and right coronary
artery injections, there was less marked QTc prolongation
in Group III (Angiovist-370) than in Groups I and II (Ren-
ografi n-76) (p < 0.00005). After angiography the QTt. in-
terval remained somewhat more prolonged in both groups
receiving Renografin-76 (Groups I and II) than in patients
receiving Angiovist-370 (Group III). at a borderline statis-
tical level (p = 0.06). The mean heart rate was not sig-
nificantly different among the three groups throughout the
cardiac catheterization (Table 2).
Discussion
Myocardial effects of contrast agents. Contrast agents
used in coronary arteriography are responsible for profound
alterations in cardiac function, including changes in heart
rate. blood pressure, peripheral resistance, coronary blood
flow, myocardial contractility and blood chemistry (17-2 1).
In addition, electrocardiographic changes have been iden-
tified, and include QRS and T wave axis shifts, bradycardia
and QT interval prolongation with the latter being linked to
contrast media-induced ventricular fibrillation (5,22- 26).
These changes in repolarization, as reflected by QTt. pro-
longation, may contribute to an increased incidence of ven-
tricular fibrill ation by producing an increased dispersion of
repolarization (27). Murdock et al. (13) postulated that with
a decrease in QTt prolongation there is a resultant decrease
in conduction delay of premature ventricular beats, and
Table 2. Mean Heart Rates*
Group I Group II Group lit
(n = 10) (n = 103) (n = 108)
Before coronary angiography 71.6 :: 6 69 .4 :: 1.3 69 .3 :: 1.2
Left coronary artery injection 86.0 :': X 69.2 :!: 1.4 69 .7 :: 1.3
Right coronary artery injection 75.4 :': X 69.3 ± 1.3 71.4 :': 1.6
After coronary angiography 77.9 :': :; 75.5 :!: 1.3 75. 3 :': 1.2
*Beatsimin ± standard error or the mean. Patient groups defined in Table I.
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therefore sufficient delay to achieve reentry is no longer
possible.
Initial attempts to decrease the incidence of ventricular
fibrillation during coronary angiography focused on the so-
dium content of contrast agents. A series of experiments
(11,18,28-30) identified an ideal concentration of sodium;
a lower concentration resulted in prolonged depolarization
and a higherconcentration in prolongedrepolarization, both
of which produced an increased incidence of ventricular
fibrillation.
Role of calcium. Calciumfluxhas alsobeen investigated
for its role in the genesis of ventricularfibrillation. Caulfield
et al. (31) observed a decrease in ionized serum calcium
levels in blood collected from the coronary sinus immedi-
ately after coronary artery injectionof Renografin-76. They
attributedthe decreaseof the ionizedcalciumto thechelating
action of sodium citrate and sodium EDTA, which are con-
tained in Renografin-76 as stabilizing agents. This finding
was further supported by Thomson et al. (6), who dem-
onstrateda lower incidenceof ventricularfibrillation in dogs
given a calcium-enriched formulation rather than the stan-
dard formulation of Renografin-76. More recently, a de-
creased incidence of ventricular fibrillation in dogs wasshown
(15) using a newer formulation of meglumine sodium dia-
trizoate, Angiovist-370, that contains as its additivecalcium
EDTA, which has less calcium-binding activity than the
additives found in Renografin-76. In addition, Murdock et
al. (15) found less QT intervalprolongation with Angiovist-
370 than with Renografin-76. In the only prospective study
performed in humans, Wolf and Hirschfeld (14) examined
the changes in QT intervals in four patients receiving either
Renografin-76 or Hypaque-76 (Winthrop Laboratories), a
contrast agent similar to Angiovist-370, which also contains
calcium EDTA as its additive. They found less QT interval
prolongation with Hypaque-76 and suggested that contrast
agents with reduced calcium-binding properties may produce
less ventricular fibrillation during coronary angiography.
Their study was limitedby inclusionof a very small number
of patients.
Present study. We prospectively examined the role of
calcium-binding additives on ventricular fibrillation during
coronary angiography in 816 patients. Several clinical and
electrocardiographic characteristics were also analyzed in a
randomly selected subset of those patients. We found a
marked reduction in the incidence of ventricular fibrillation
when using Angiovist-370 (calcium EDTA as additive) as
compared with Renografin-76 (sodium citrate and sodium
EDTA as additives). Patients receiving Angiovist-370 had
significantly less QT interval prolongation during coronary
artery injections as compared with patients receiving Ren-
ografin-76. These results indicate that the incidence of ven-
tricular fibrillation during coronary angiography, as well as
QTc prolongation (14), can be reduced by eliminating the
calcium-binding additives found in contrast agents.
Our study also suggests that baseline repolarization ab-
normalities may contribute to the incidence of ventricular
fibrillation. The QT interval before coronary angiography
was higher in Group I (ventricular fibrillation) than in Groups
II and III (Renografin-76 and Angiovist-370 without ven-
tricular fibrillation). While this difference is not statistically
significant, it supports previously published data (32) in a
largergroupof patientswith ventricularfibrillation in whom
QT interval prolongation before angiography was found to
be an importantrisk factorfor thedevelopmentof ventricular
fibrillation.
Study limitations. Our study is limited by the fact that
comparisons were made between patients with ventricular
fibrillation (Group I) and a random sample of the patients
receiving Renografin-76 (Group II) and Angiovist-370 (Group
III) who were arrhythmia free. This limitation is mitigated
by the apparent similarity of the three groups with respect
to clinical characteristics and extent of coronary disease.
An additional limitation is that QT interval measurements
are subject to interobserver and intraobserver variations (33).
Our study providedfor a blinded analysis of the data, which
partially obviates that bias. Nonionic contrast agents were
notevaluatedin our study, but theyalso reduce the incidence
of ventricular fibrillation when comparedwith ionic contrast
agents (8,9,17). Calcium-enriched forms of meglumine so-
dium diatrizoate, which are comparably priced with similar
contrastmediausingsodiumEDTA as their additive, appear
to be more reasonable alternative contrast agents in view of
their markedly reduced incidence of ventricular fibrillation.
Finallyother factors, such as quantityof contrast agent used
with each coronary injection, as well as changes in con-
duction and automaticity, were not analyzed but may be as
important as repolarization abnormalities in the genesis of
ventricular fibrillation during coronary angiography.
We thank Adele Kaplan for statistical analysis and the cardiac catheter-
ization laboratory personnel, in particular the late Susan Dietsch, for their
participation in this study, and Nancy Scudder and Donna Simonds for
careful preparation of the manuscript.
References
I. Davis K, Kennedy JW, Kemp HG, Judkins MP, Gosselin AJ,
Killip T. Complications of coronary arteriography from the collabo-
rative study of coronary artery surgery (CASS). Circulation 1979;59:
1105-1 I.
2. Adams OF, Fraser DB, Abrams HL. The complications of coronary
arteriography. Circulation 1973;48:609- I8.
3. Gwost J, Stoebe T, Chesler E, Weir EK. Analysis of the complications
of cardiac catheterization over nine years. Cathet Cardiovasc Diagn
1982;8:I3-21.
4. Lehmann MH, Cameron A, Kemp HG. Increased risk of ventricular
fibrillation associated with temporary pacemaker use during coronary
arteriography. PACE 1983;6:923-9.
5. Nishimura RA, Holmes DR, McFarland TM, Smith HC, Bove AA.
Ventricular arrhythmias during coronary angiography in patients with
lACC Vol. 10. No.6
December 1987: 1249-53
ZUKERMAN ET AL.
VENTRICULAR FIBRILLATION DURING CORONARY ANGIOGRAPHY
1253
angina pectoris or chest pain syndromes. Am J Cardiol 1984;53:
1496-9.
6. Thomson KR. Violante MR, Kenyon T, Fischer HW. Reduction in
ventricular fibrillation using calcium-enriched Renografin-76. Invest
RadioI1978;13:238-40.
7. Wolf GL, Kraft L, Kilzer K. Contrast agents lower ventricular fi-
brillation threshold. Radiology 1978;129:215-7.
8. WolfGL. The fibrillatory propensities of contrast agents. Invest Radiol
1980;15(suppl):5208-14.
9. Tragardh B, Lynch PRo ECG changes and arrhythmias induced by
ionic and non-ionic contrast media during coronary arteriography in
dogs. Invest Radiol 1978;13:233-7.
10. Gensini GG, DiGiorgi S. Myocardial toxicity of contrast agents used
in angiography. Radiology 1964;82:24-33.
II. Simon AL, Shabetai R, Lang JH, Lasser Ee. The mechanism of
production of ventricular fibrillation in coronary angiography. Am J
Roentgenol 1972;114:810-6.
12. Popio KA, Ross AM, Oravec JM, Ingram JT. Identification and de-
scription of separate mechanisms for two components of Renografin
cardiotoxicity. Circulation 1978;58:520-8.
13. Murdock DK, Euler DE, Becker DM, Murdock JD, Scanlon PJ,
Gunnar RM. Ventricular fibrillation during coronary angiography: an
analysis of mechanisms. Am Heart J 1985;109:265-73.
14. Wolf GL, Hirschfeld JW. Change in QT, interval induced with Ren-
ografin-76 and Hypaque-76 during coronary arteriography. J Am Coli
Cardiol 1983;1:1489-92.
15. Murdock DK, Euler DE, Kozeny G, Murdock JD, Loch HS, Scanlon
PJ. Ventricular fibrillation during coronary arteriography in dogs: the
role of calcium-binding additives. Am J Cardiol 1984;54:897-901.
16. Bazell HC. An analysis of the time relationship of the electrocardio-
gram. Heart 1920;7:353-70.
17. Hanley PC, Holmes DR, Julsrud PR, Smith He. Use of conventional
and newer radiographic contrast agents in cardiac angiography. Prog
Cardiovasc Dis 1986;28:435-48.
18. Fischer HW, Thomson KR. Contrast media in coronary arteriography:
a review. Invest Radiol 1978;13:450-9.
19. Benchimol A, McNally EM. Hemodynamic and electrocardiographic
effects of selective coronary angiography in man. N Engl J Med
1966;274: 1217-24.
20. Gootman N, Rudolph AM, Buckley NM. Effects of angiographic
contrast media on cardiac function. Am J Cardiol 1970;25:59-65.
21. Gensini GG, Dutrel J, Huntington PP, Kelly AE. Left ventricular end-
diastolic pressure before and after coronary arteriography. Am J Car-
diol 1971;27:453-9
22. Grendahl H. Eie H. Nordvik A, Muller e. Electrocardiographic changes
during selective coronary angiography. Acta Med Scand 1972;191:
493-500.
23. MacAlpin RN. Weidner WA, Kallus AA, Hanafee WN. Electrocar-
diographic changes during selective coronary cineangiography. Cir-
culation 1966;34:627-37.
24. Eie H. Grendahl H, Nordvik A. Muller e. Electrocardiographic changes
during selective coronary angiography. Acta Radiol lDiagn] (Stockh)
1972;12:554-60.
25. Maytin O. Castillo C, Castellanos A, Jr. The genesis of QRS changes
produced by selective coronary arteriography. Circulation 1970;41:
247-55.
26. Tragardh B. Bove AA, Lynch PRo Mechanism of production of cardiac
conduction abnormalities due to coronary arteriography in dogs. Invest
Radiol 1976;11:563-8.
27. Surawicz B, Knoebel SB. Long QT: good. bad or indifferent? JAm
Coll Cardiol 1984:4:398-413.
28. Paulin S, Adams DF. Increased ventricular fibrillation during coronary
arteriography with a new contrast medium preparation. Radiology
1971;101:45-50.
29. Snyder CF. Forman KA. Frech RS, Amplatz K. The role of sodium
in promoting ventricular arrhythmia during selective coronary arteri-
ography. Am J Roentgenol 1971;113:567-71.
30. Smith RF. Harthome JW. Sanders CA. Vectorcardiographic changes
during intracoronary injections. Circulation 1967;36:63-76.
31. Caulfield JB, Ziv L. Harthome lW. Blood calcium levels in the pres-
ence of arteriographic contrast material. Circulation 1975;52: 119-23.
32. Arrowood JA, Mullan DF, Kline RA. Engel TR, Kowey PRo Ven-
tricular fibrillation during coronary angiography: the precatheterization
QT interval. J Electrocardiol 1987;20:255-9.
33. Ahnve S. Errors in the visual determination of corrected QT (QT,)
interval during acute myocardial infarction. J Am Coll Cardiol 1985;5:
699-702.
